Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens

Inhibikase Therapeutics

14/11/2025 21:09

Overview

Inhibikase Q3 net loss widens to $11.9 mln, driven by increased R&D and SG&A expenses

Cash reserves drop to $77.3 mln from $97.5 mln at year-end 2024

Result Drivers

EXECUTIVE TRANSITIONS - SG&A expenses rose due to executive transitions, including severance costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.13
Q3 Net Income
-$11.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Inhibikase Therapeutics Inc is $8.00, about 80% above its November 13 closing price of $1.60

Press Release: ID:nGNX1nL2l3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)